Premium
Pregnancy and symptomatic relief following ultrasound‐guided transvaginal radiofrequency ablation in patients with adenomyosis
Author(s) -
Nam JangHyun
Publication year - 2020
Publication title -
journal of obstetrics and gynaecology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 1341-8076
DOI - 10.1111/jog.14145
Subject(s) - medicine , adenomyosis , pregnancy , radiofrequency ablation , blood loss , obstetrics , surgery , endometriosis , ablation , gynecology , genetics , biology
Aim To report the reproductive results and symptomatic relief of patients with adenomyosis who attempted to conceive after ultrasound‐guided radiofrequency ablation (RFA). Methods Of 182 consecutive patients with adenomyosis who had undergone RFA, only 81 patients were eligible for this study. Pregnancy outcomes, postoperative complications, preoperative and postoperative pictorial blood loss assessment chart scores, and pain scores were evaluated. Results Of these 81 patients, 74 were infertile and seven were single at the time of RFA. The mean age at the time of operation was 35.8 years. The mean duration from the time of RFA to conception was 18.9 months (range, 2–72 months). Fifty‐nine patients tried natural conception, while 22 patients attempted conception with assisted reproductive techniques. Twenty‐nine (35.8%) patients achieved 39 pregnancies. Except for the 23 patients who did not actively try to conceive and who inevitably or arbitrarily discontinued pregnancy attempts, the pregnancy success rate reached 50%. Twenty‐two (84.6%) of the 29 patients delivered 24 (66.7%) live babies (nine vaginal deliveries and 15 cesarean sections). Twelve (33.3%) pregnancies ended in spontaneous abortions. No uterine ruptures occurred. Paired sample t ‐tests revealed that preoperative pictorial blood loss assessment chart and pain scores were significantly ( P < 0.05) different from the postoperative scores at 1‐, 3‐ and 6‐months. Conclusion RFA could be considered a minimally‐invasive treatment option for patients with adenomyosis who desire to maintain fertility and alleviate symptoms.